SCHEMBL14934285

SCHEMBL14934285

Cc1ccc(OC(C)(C)C(=O)O)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 13/20 0.53
PPARD Q03181 12/20 0.53
PPARG P37231 7/20 0.53
CYP2C9 P11712 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP1A2 P05177 2/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
TTR P02766 1/20 0.44
CYP2C8 P10632 1/20 0.44
CHRM1 P11229 1/20 0.44
TSHR P16473 1/20 0.44
ADRA1A P35348 1/20 0.44
HTR2B P41595 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLCO1B3 Q9NPD5 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CISD1 Q9NZ45 1/20 0.44
SLCO1B1 Q9Y6L6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599895 0.86 CYP2C9 (0.59) PPARAPPARDPPARGCYP2C9KDM4E
SCHEMBL3930336 0.84 KDM4E (0.45) PPARAPPARDPPARGKDM4EALDH1A1
SCHEMBL2432253 0.83 KDM4E (0.47) PPARAPPARDPPARGKDM4EALDH1A1
SCHEMBL16348228 0.83 ACHE (0.55) PPARAPPARDPPARGCYP2C9KDM4E
SCHEMBL7978183 0.83 PPARA (0.57) PPARAPPARDPPARGCYP2C9KDM4E
SCHEMBL17908034 0.83 CA12 (0.47) PPARAPPARDPPARGKDM4EALDH1A1
SCHEMBL14110371 0.81 PPARA (0.45) PPARAPPARDPPARGCYP2C9KDM4E
SCHEMBL6362308 0.80 FBP1 (0.47) PPARAPPARDPPARGKDM4EALDH1A1
SCHEMBL15801266 0.80 PPARD (0.50) PPARAPPARDPPARGKDM4EALDH1A1
SCHEMBL13180019 0.79 CYP2C9 (0.45) PPARAPPARDPPARGCYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365588-B2 Benzoxazines as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 US disclosed
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-16 US disclosed
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
WO-2013067248-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-10 WO disclosed
US-20110306607-A1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-15 US disclosed
US-20110306607-A1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171427-A1 Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels KCNJ2, TRPV1, KCNJ1 PPARA 568/4885PPARD 348/4885PPARG 508/4885
US-20110306607-A1 HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, TRPV1, KCNJ1 PPARA 568/4885PPARD 348/4885PPARG 508/4885
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS KCNJ1, KCNJ2, KCNJ11 PPARA 1268/4885PPARD 1060/4885PPARG 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.